Earnings summaries and quarterly performance for Vivani Medical.
Executive leadership at Vivani Medical.
Board of directors at Vivani Medical.
Research analysts who have asked questions during Vivani Medical earnings calls.
Recent press releases and 8-K filings for VANI.
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
VANI
- Vivani Medical, Inc. announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share.
- Concurrently, a private placement of 1,351,351 shares of common stock was priced at $1.48 per share and purchased by Gregg Williams, the Chairman of the Company’s board of directors.
- The gross proceeds to the Company from both offerings are expected to be approximately $4.5 million.
- The net proceeds are intended to fund ongoing research and clinical development of product candidates, as well as for working capital and general corporate purposes.
- The registered offering and private placement are expected to close on or about January 27, 2026.
Jan 27, 2026, 9:11 PM
Vivani Medical Reports Q3 2025 Results and Business Updates
VANI
Earnings
New Projects/Investments
Guidance Update
- Vivani Medical reported its financial results for the third quarter ended September 30, 2025, with key figures detailed below :
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Research and development expense ($USD Millions) | $4.2 | $4.5 |
| General and administrative expense ($USD Millions) | $2.1 | $2.2 |
| Net Loss ($USD Millions) | $(6.0) | $(6.5) |
- As of September 30, 2025, Vivani had cash, cash equivalents, and restricted cash totaling approximately $4.0 million.
- Recent financings in Q3 2025 and October 2025 generated approximately $25.7 million in gross proceeds and commitments, securing the company's financial position into 2027.
- The company plans to initiate a Phase 1 clinical study for its semaglutide implant (NPM-139) for chronic weight management in the first half of 2026.
- The record date for the planned spin-off of its subsidiary, Cortigent, was temporarily withdrawn due to the U.S. federal government shutdown, with a new date expected after the SEC resumes operations.
Nov 13, 2025, 1:00 PM
Vivani Medical Outlines Plans for Semaglutide Implant Clinical Development
VANI
New Projects/Investments
- Vivani Medical is focused on developing a six-month semaglutide implant (NPM-139) for chronic weight management, utilizing its NanoPortal drug delivery technology to enhance patient adherence and tolerability for GLP-1 receptor agonists.
- The company plans to initiate clinical development for the semaglutide implant in the first half of next year (2026), building on preclinical data that demonstrated sustained 20% weight loss over a seven-month period from a single implant.
- Vivani Medical positions its implant as the only GLP-1 implant actively in development for obesity, aiming to offer convenient once or twice-yearly dosing to address significant unmet needs in the market.
Oct 30, 2025, 5:30 PM
Vivani Medical Prices Common Stock Offering
VANI
New Projects/Investments
- Vivani Medical, Inc. announced the pricing of a registered direct offering of 6,000,000 shares of common stock at $1.62 per share.
- A concurrent private placement of 3,703,703 shares of common stock at the same price was made to Gregg Williams, the Chairman of the board.
- The combined offerings are expected to generate gross proceeds of approximately $15.7 million.
- The company intends to use the net proceeds to fund ongoing research and clinical development of product candidates, as well as for working capital and general corporate purposes.
- The offerings are anticipated to close on or about October 28, 2025.
Oct 28, 2025, 10:03 AM
Vivani Medical Inc. provides update on NanoPortal platform and semaglutide implant development
VANI
New Projects/Investments
Dividends
- Vivani Medical Inc. (VANI) is developing subdermal biopharmaceutical implants using its NanoPortal platform to address medication non-adherence and improve tolerability in chronic diseases, initially focusing on the GLP-1 space for obesity and diabetes.
- The company successfully completed a first-in-human study with its technology earlier in 2025, demonstrating positive safety, tolerability, and encouraging performance.
- Vivani Medical's lead program is a semaglutide implant (NPM 139), which showed approximately 20% preclinical weight loss over seven months. Clinical development for this implant is anticipated to begin in the first half of 2026 with a Phase 1 study.
- The GLP-1 market for chronic weight management generated over $14 billion in sales in 2024 and is projected to grow at a 32% compound annual growth rate until the early 2030s.
- Vivani Medical is spinning off its subsidiary, Cortigen, with shareholders holding common stock as of October 8th eligible to receive a dividend of Cortigen shares.
Sep 25, 2025, 5:45 PM
Vivani Medical Details Progress on GLP-1 Implant Programs and Cortigent Spin-off
VANI
New Projects/Investments
Dividends
- Vivani Medical Inc. (VANI) is developing subdermal biopharmaceutical implants using its proprietary NanoPortal platform to address medication non-adherence in chronic diseases, with an initial focus on the GLP-1 space for obesity and diabetes.
- The company's lead program, a semaglutide implant (NPM 139), demonstrated approximately 20% weight loss over a seven-month period in preclinical studies.
- Following a successful first-in-human study for its exenatide implant technology, Vivani Medical anticipates initiating clinical development for the semaglutide implant in the first half of next year.
- Vivani Medical announced a spin-off of its subsidiary, Cortigent, with shareholders holding common stock as of October 8 eligible to receive a dividend of Cortigent shares.
Sep 25, 2025, 5:45 PM
Vivani Medical Announces Record Date for Cortigent Spin-off
VANI
M&A
New Projects/Investments
- Vivani Medical, Inc. (VANI) has set October 8, 2025, as the record date for the spin-off of its wholly-owned subsidiary, Cortigent, Inc..
- Vivani stockholders holding common stock as of the record date will receive common stock in Cortigent. Cortigent, which develops brain implant devices with neuromodulation technology, is expected to trade on the Nasdaq Stock Market under the ticker symbol "CRGT".
- Following the spin-off, Vivani Medical will sharpen its focus on developing miniature, ultra long-acting GLP-1 implants for weight loss management and type 2 diabetes. The spin-off is estimated to be complete by late-2025.
Sep 17, 2025, 1:27 PM
Quarterly earnings call transcripts for Vivani Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more